The interaction of neuroimmunology, neuromodulator, and neurotransmitter with nociceptor and MAPK signaling by Dewi, Dewa Ayu Mas Shintya & Wiryana, Made
REVIEW ARTICLE
Bali Journal of Anesthesiology (BJOA) 2019, Volume 3, Number 1: 44-49
E-ISSN: 2549-2276
44 Open access: www.bjoa.balijournals.org
CrossMark
Published by DiscoverSys
INTRODUCTION
Pain is an unpleasant sensory and emotional 
experience associated with actual or potential 
tissue damage or described in terms of such 
damage.1 Pain can be physiological or patho-
logical pain or described as clinical pain.2 
Physiological pain is an acute nociception pain 
as a protective mechanism against tissue damage 
or threat to tissue damage caused by activation 
nociception pathway by adequate peripheral 
intensity stimuli.2,3 Physiological pain starts from 
the terminal nociceptor of the skin and muscles, 
transmitted to the small diameter unmyelin-
ated C nerve fibers (slow conducting) and A 
myelinated nerve fibers (fast conducting) that is 
a sensitive polymodal nociceptor of mechanic, 
thermal and chemical stimuli.4 Nociceptors are 
pain receptor located at the end organ of the 
skin, muscle, joint, and viscera, free encapsulated 
and selectively responds to noxious or threats to 
tissue damage.5,6 The structures of nociceptors 
are spread as an axon, cell body, and central 
terminal related to the end organ, the cell body 
has a small diameter located at the dorsal root 
ganglia and sensory ganglia.5,7 Expression of the 
ligand-gated ion channel and voltage-gated ion 
channel includes TRPV1, TRPA1, Nav1.7, Nav 
1.8 and Nav 1.9 which are the key of transduction 
molecule noxious stimuli.4,8 The first nociceptor 
will respond when the nervous system propa-
gates signals in a few milliseconds when there is 
a pathogen or tissue damage. 
INFLAMMATION PAIN
Pathological pain is related to inflammation 
pain and neuropathic pain. Inflammation pain 
is pain following tissue damage either caused by 
mechanical, thermal, chemical, tissue ischemia 
and infection pathogen stimuli.9 Neuropathic pain 
is related to peripheral and central nerve damage. 
Inflammation response is tissue control as a 
protection mechanism, but when it is over it will 
cause tissue damage and pathological condition, 
because the activation of target cell does not only 
affect the initial inflammation location but also in 
other locations which respond to the inflammation 
stimuli.9 Inflammation mediator directly stimulates 
and sensitize the peripheral nociceptor located at 
the primary afferent nerve fibers at the peripheral 
tissue (dorsal ganglion and terminal ganglia).10–12 
The hyperactivity of primary sensory nerve fibers 
following an inflammation will also induce produc-
tion of neurotransmitters (dopamine, acetylcho-
line, serotonin, glutamate), neuropeptide and 
neuromodulator (adenosine, purine, ATP, NO) at 
the central terminal of the primary afferent nerve 
fibers, spinal chord and trigeminal nucleus which 
cause postsynaptic nociceptive neuron hyperactiv-
ity (central sensitization). Most acute pain (surgical 
incision, ankle sprained, burn) will heal without 
permanent pain, this showed the nociceptor sensi-
tization is temporary7 Acute inflammation follow-
ing the sensitization process is permanent and 
will cause chronic pain. Physiological threshold 
decrease with a noxious stimulus, as in cutaneous 
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Physiological pain is a protection mechanism against tissue damage 
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and mechanic through MAPK signaling, then neuromodulator and 
neurotransmitter at the afferent nerve endings will regulate the innate 
immune response, adaptive and vascular. 
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nociceptor sensitized by thermal stimuli and deep 
tissue nociceptor (muscle and joint) sensitized by 
mechanical stimulus.4,13 
The innate immune cell is located at the tissue, 
includes macrophage, fibroblast, mast cell, mono-
cyte, and neutrophil, identifies pathogen invasion 
when there is an invasion or cell damage through the 
expression of pathogen recognize receptor (PRRS).14 
The initial response of tissue damage known as 
sterile inflammation is mediated by damage-associ-
ated molecular pattern (DAMPs), if it is caused by 
pathogen will be mediated by pathogen-associated 
molecular pattern (PAMPs). DAMP is a heterogenic 
molecule group from the extracellular and intracel-
lular compartment activating the immune system 
through PRRS when there is tissue damage.15–17 
Biglycan, decorate, fibrinogen, fibronectin, hyal-
uronan is an extracellular DAMPs. HMGB1, histon, 
DNA, RNA are from the nucleus, ATP, DNA is from 
mitochondria while uric acid, heat shock proteins, 
S100A, S100B are from the cytosol.17 DAMP and 
PARS will activate PRRS i.e. Toll-Like Receptors 
(TLRs), The Receptor for advanced glycation end 
products (RAGE) and NLRP3 inflammasome.15,17,18 
Activated oligomerisated PRRS and union of most 
multisubunit will initiate signal cascade, stimulate 
productions of leukocyte recruitment factors.19 
Extracellular DAMP as in ATP, mitochondria form-
aldehyde peptide and mtDNA has an important role 
in neutrophil recruitment in sterile injury followed 
by other cytokines.20 The neutrophil is an initial 
injury response released in a few hours, followed 
by macrophage in a few days and cell T infiltra-
tion in a few days until a few weeks.21 Macrophage 
releases IL-1β, TNF-α, bradykinin, 5-HT, IL-6 and 
NGF (Nerve Growth Factor), has an important 
role in initiating, inflammation development and 
resolution, cleaning damaged cells and pathogen by 
phagocytosis and activating immune cell as neutro-
phil, dendrite cell, macrophage, and monocyte. 
The injury also involves the mast cell to produce 
bradykinin, serotonin, prostaglandin. All of those 
endogen substance work in each receptor known 
as the primary afferent nociceptor will generate 
the second messenger as Ca and cyclic AMP then 
activate multiple protein kinase i.e. protein kinase 
A (PKA), protein kinase C (PKC), extracellular 
signal-regulation kinase (ERK) and p38 MAPK 
and JUN N-terminal kinase (JNK). Activation of 
some protein kinase will result in sensitization by 
translational, posttranslational and transcriptional 
regulation, especially ERK and p38 which are acti-
vated by inflammation mediators in the primary 
sensory and second-order neuron of the dorsal 
horn that participates in generation and mainte-
nance of inflammation pain.14,22 Inflammation pain 
is manifested as spontaneous pain and hypersen-
sitivity pain, spontaneous pain is a direct specific 
receptor and terminal nociceptor activation by 
inflammation mediators. Hypersensitivity pain is a 
consequence of posttranslational changes or acute 
posttranslational modification at the peripheral 
terminal nociceptor and the dorsal horn of the 
spinal cord continuing at the transcription of the 
effector gene, this repeats at the primary sensory 
and dorsal horn of the spinal cord responsible of 
the inflammation neuroplasticity.23–25
Kinase activation increase nociceptor sensitivity 
and excitability are known as peripheral sensiti-
zation through a different mechanism. Potential 
cathion channel receptor subfamily A member 1 
(TRPA1), potential vanilloid 1 receptor (TRPV1), 
voltage gate-ion channel Nav 1-.7, Nav 1.8, Nav1.9 
has an important role in molecule transduction and 
conduction involved in the primary sensitization 
process. Nociceptor neuron also expresses Toll-like 
receptor (TLRs) activated by endogen or exogen 
ligand.21
The immune system has an important role in 
pain pathophysiology. Tissue immune response 
will affect the neuroimmune system at neuronal 
sensitization, therefore the neuroimmune mech-
anism in neuron sensitization should be under-
stood. Neuron nociceptor express receptors for 
cytokine immune cell, lipid protease and growth 
factor. During activation through phosphorylation 
or another mechanism will mediate channel ion 
cascade TRPVi, TRPA1, Nav 1.7, Nav1.8 and Nav 
1.9. therefore increase neuronal threshold. Potential 
action is transmitted to the cell body receptor in the 
DRG and forwarded to the spinal cord and brain to 
mediate the process of pain.7
Figure 1  Modulation of nociceptor on neuroimmune, neuromodulator and 
neurotransmitters
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IL-1β is the first cytokine involved in hyperalge-
sia process13 DAMP activated cytokine production 
by activation of PRRs and caspase 1. Caspase 1 
(cysteine-aspartic protease, cysteine aspartase, or 
cysteine dependent aspartate-directed proteases) 
is a family of protease enzyme involved in cell 
death program (apoptosis, pyroptosis, necroptosis) 
and inflammation, to maintain cell homeostasis.26 
Caspase 1 is named as ICE interleukin 1β convert-
ing enzyme activates pro IL-1β to IL-β.13,27,28 cause 
immune cell recruitment towards the infected 
or damaged tissue cell29 IL-1β increase TRPV1 
expression through activation of IL1R1 which will 
increase thermal stimulus sensitivity, also sensitize 
neuron NaV 1,8 sodium channel receptor that 
will cause mechanical and thermal hyperalgesia 
through p38 MAPK phosphorylation.13,27,28 IL-1R 
is at the nonneuronal cell, mostly expressed at the 
DRG and dorsal horn of the spinal cord. The cyto-
kine involved in permanent pain is not limited at 
peripheral sensitization, but the proinflammatory 
cytokine and their receptors are also localized at 
the dorsal horn and brain.30–3and increased during 
induced mice arthritis by CFA.8 As a response to 
the ligand bond with the receptor it activates intra-
cellular signaling through p38, nuclear factor kappa 
B (NF-kB) and JNK activate. MAPK Intraplantar 
IL-1β injection increase the mechanical and ther-
mal sensitivity, does not decrease with the admin-
istration of ibuprofen but decrease with adding 
p38 MAPK inhibition.31,32 Activation signaling 
NfKb, JNK, and p38MAPK induce the expression 
of canoninal IL-1 target genes by transcriptional 
dan posttranscriptional. IL-6 also contributed to 
the inflammation pain process by increasing pros-
taglandin production and combined as an al gp130 
transducer signal produce expression of TRPV1 
and TRPA1.
TNF has a role in the pain process pathway 
through activation of TNF subunit receptor i.e. 
TNFR1 and TNFR2, where TNFR2 has a more 
important role in neuron excitability modulation.32 
Forty until fifty percent of TNFR1 and TNFR2 is 
expressed in the DRG neuron, with the immuno-
histochemical and immunofluorescence examina-
tion increased from the basal level during nerve 
trauma.32–35 Intraarticular injection of etanercept 
(TNFR fusion protein) reduce the sensory nerve 
fiber response (A delta and C) against mechani-
cal stimulus for 30 minutes after injection.33 With 
PCR analysis of the DRG of naive mice the TNFR1 
is only expressed at the neuron, while TNFR2 in 
the nonneuron cell with analysis.8 TNF increase 
rapidly from the thermal and mechanical stimulus 
of the inflamed knee. TNF-α sensitizes receptor 
Nav 1.8 and Nav 1.9 through TNFR1, therefore, 
affect the neuron excitability through p38 MAPK 
phosphorylation, while TNFR2 will increase 
TRPV1 expression which causes thermal hyperal-
gesia.35,37 In the cultured DRG neuron stimulated 
by TNF there is activation of p38 MAPK and c-Jun 
N-terminal kinase (JNK), but not at p42/p44 (extra-
cellular signal-signal regulate proteinkinase1 and 2 
(ERK1/2).32,38,39 But TNF is confirmed to mediate 
upregulation expression of TRPV1 at murine DRG 
neuron through p42/p44.37 In the pathway of pain 
process, TNF cannot act solely as a mediator in pain 
induction. 
The role of adenosine in the nociception process 
was first found in 1970, then investigated more 
thoroughly in 1980 with the administration of 
selective agonist intravenously and intrathecally.40,41 
Adenosine works in several subtype G-protein 
adenosine receptor involved in peripheral, spinal 
and supraspinal pain signaling. Adenosine has four 
subunit receptors, i.e. A1Rs, A2ARs, A2BRs, and 
A3Rs. Receptor A1s, A2As is located at the termi-
nal end of the sensory nerve,39,40,42 while A2BRs and 
A3Rs has a direct border with the nociception cell 
type (mast cell) examined from immunohistochem-
ical,41–44 contributed indirectly to the inflammation 
reaction through inflammation mediator41 A1Rs is 
also widely expressed at the transmission area and 
pain regulator at the central nervous system (spinal 
chord) specifically the microglia contributes to the 
pain process in the central, either in physiological, 
inflammatory or neuropathic pain.45 Adenosine has 
a variable high affinity to A1Rs, A2ARs, A2BRs, 
and A3Rs, some cases have the same affinity to the 
subtype receptors.43 Activation of A1s and A2As 
receptors cause antinociception effect.46 Some 
inflammation studies use the caragenan, formal-
dehyde, surgical incision model.47,48 Some studies 
use the neuropathic pain model, such as spinal cord 
trauma48 and diabetic nephropathy49,50 show A1Rs 
agonist have analgesia and antihyperalgesic effect. 
Part of the A1Rs signaling pathway will inhibit 
cyclic AMP/PKA and interact with the Ca+ dan K+ 
channel through Ga, interact with PLC/IP3/ DAG 
pathway through Ga subunit or bc and b-arresting 
mediating receptor and downregulation. Adenosine 
can activate ERK1/2, p38, and JNK in the rabbit 
heart, therefore there is a possible clear relationship 
between the adenosine receptor and MAPK.51
Neurotrophins include nerve growth factor 
(NGF), brain derived growth factor (BDNF), 
neurotrophin 3 (NT3) and neurotrophin 4 is a 
family of small secreted protein which has a role 
to maintain functional physiological activity of 
neurons to regulate life, growth, and differentiation 
of synapse creation, plasticity related to the neuron 
during growth process.52–54 NGF is the most abun-
dant neurotrophin, secreted by the nonneural tissue 
target cell, i.e. skin, muscle, testicle, and salivary 
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glands.55 NGF work through two receptor classes, 
i.e. tropomyosin-related kinase (TrkA) which takes 
the tyrosine kinase activity at the intracellular 
domain and p75 neurotrophin (p75NTR) receptor 
which is the death receptor family.55 The binding of 
TrkA and NGF cause phosphorylation of TrkA on 
the tyrosine residue and kinase activity followed by 
activation of the MAPK cascade.56,57 Also phospha-
tidylinositol 3 kinases (PI3K-Akt) and phospholi-
pase C pathway. This pathway eventually will cause 
cellular proliferation, differentiation and life activa-
tion of p38 at the dorsal root ganglia (DRG) from 
NGF peripheral production during inflammation 
process and retrogradely will increase TRPV1 level 
which contributes to maintaining heat hypersen-
sitivity during inflammation.58 Further studies 
show TRPV1 ion channel mediated by NGF cause 
thermal and mechanical hypersensitivity in mice.59 
TRPV1 mechanism and the oxidative mechanism 
through NGF permanent effect cause thermal 
hypersensitivity through peripheral action, spinal 
and mechanical allodynia through spinal action 
which needs de novo protein.60 NGF regulates 
sensory activity, affects neuronal function through 
CGRP expression and plays an important role 
in the ERK5 / CREB signal transduction process 
during inflammatory pain. In DRG some sensory 
neurons are peptidergic neurons derived from 
calcitonin gene-related peptide (CGRP) which is 
very closely related to NGF.61 After NGF binds to 
TrKA on neurons it will activate several pathways 
simultaneously including the ERK5 / CREB path-
way which will increase gene expression and play 
a role in neural plasticity through BDNF expres-
sion. Regulation of BDNF activity through MAPK 
contributes to persistent inflammatory pain and 
neuropathic pain.61–63
Glutamate is a neurotransmitter produced by 
primary afferent nerve fibers, it activates postsyn-
aptic glutamate receptor at the dorsal horn of the 
spinal cord. Inotropic receptor (AMPA, kainate, 
NMDA) and metabotropic are also expressed at 
the presynaptic terminal end of the afferent nerve 
fibers that regulate the production of neurotrans-
mitters.64 The production of glutamate at the 
axonic synaptic axon is irrelevant with the GluR 
presynaptic activity therefore further study is 
needed to know the presynaptic GluR physiol-
ogy.64,65 The NMDA receptors are of NR1, NR2 (A, 
B, C, D) and NR3 (A,B) subunits which are iono-
tropic receptors with special attention for its role 
in excitation synapse transmission and plasticity.66 
Some articles mention that NMDA receptor 
activation during tissue damage and inflamma-
tion will facilitate the process at DRG and spinal 
cord.64,67,68 The NMDA receptor at microglia of 
the spinal cord has a role in the process of periph-
eral inflammatory pain induced by the venom in 
mice.68 NMDA receptors expressed at the DRG 
participates in the primary afferent neuron exci-
tation modulation which has a role in primary 
sensitization in inflammation.69 Inflammation 
induction with carrageenan will increase the 
NMDA receptor function in the spinal cord in 
the nociception transmission.67 Gene expression 
regulation by the glutamate receptor will increase 
the intracellular signaling cascade activation 
phosphorylation factor through MAPK protein 
kinase activating mitogen (ERK, JNK, and p38). 
Some studies show an increase of ERK phosphor-
ylation is an activation response of the NMDA 
receptor that activation of ERK 5 through the 
NMDA receptor is a nociception signaling trans-
mission block.63,70 ERK5 and ERK1/2 regulates cell 
signaling transduction that is a homolog of ERK/
CREB pathway in the DRG and spinal cord has a 
role in pain hypersensitivity and allodynia after 
peripheral inflammation.63
CONCLUSION
Pain following tissue damage by mechanical, 
temperature and chemical stimuli cause an inflam-
matory response either temporary or permanent. 
The inflammation mediators released during 
inflammation response will activate each receptor, 
ILB activates IL1R1 and TNF activates TBFR1 and 
TNFR1 followed by activation of some other neuro-
modulator receptors i.e. adenosine, neurotrophin, 
and glutamate neurotransmitter. All endogenous 
substance that activates its own receptor will gener-
ate a second messenger which will, in turn, activate 
some other protein kinases such as protein kinase 
A (PKA), protein kinase C (PKC), extracellular 
signal-regulation kinase (ERK) and p38 MAPK and 
JUN N-terminal kinase (JNK). The kinase activity 
increases the nociceptor sensitivity and excitability 
known as peripheral sensitization by a different 
mechanism, the translational and transcriptional 
regulation. The activation of protein kinase A 
and C is temporary through posttranslational 
regulation while the MAPK activation through 
posttranslational and transcriptional regulation. 
The translational and transcriptional regulation 
through MAPK activation is related to permanent 
inflammation pain. The activation of each specific 
nociceptor to the specific MAPK is through a quite 
complex cross communication. ERK and p38 acti-
vated by inflammation mediators at the primary 
sensory and second-order neuron of the dorsal 
horn participates in generating and maintaining 
inflammation pain. 
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